Chapter review

Fitzgerald PMHNP board review. ch14. Older Adults. This is drive 4 of 7. When I say Pause. Answer. wait, then I will give the answer. New section. Master Comparison Matrix of MNCD Subtypes. Topic. Alzheimer’s Disease (AD). Bottom Line Summary. - **Alzheimer's disease** is the most common cause of **major neurocognitive disorder**, characterized by gradual cognitive decline and average survival of **6 to 9 years** after diagnosis [1, 2]. - Core neuropathology consists of extracellular neuritic **amyloid plaques** and intracellular neurofibrillary **tau tangles** source 3. - **First-line** pharmacotherapy for mild to moderate stages consists of **acetylcholinesterase inhibitors** (**donepezil**, **rivastigmine**, **galantamine**), while **memantine** is added for moderate to severe stages [4-6]. - **Safety alert**: **second-generation antipsychotics** carry a **boxed warning** for a **1.6 to 1.7 times** increased risk of death in elderly patients with NCD-related psychosis, primarily from cardiovascular events or pneumonia [7, 8]. - **Board trap**: **acetylcholinesterase inhibitors** provide minor, temporary cognitive stabilization and do not restore patients to their pre-disease baseline [9, 10]. - Up to **50%** of patients with **major neurocognitive disorder** have co-occurring depression, which should be evaluated and treated with an **SSRI** [11-13]. - Routine genetic testing for the **ApoE e4 allele** is not recommended for clinical diagnosis, but genetic testing is indicated for early-onset cases occurring before age **65** [14, 15]. Clinical Teaching: Alzheimer's Disease and Subtype Comparison. Clinical Profile and Diagnostic Features. **Alzheimer's disease** is the leading cause of **major neurocognitive disorder** source 1. The clinical course begins insidiously with progressive decline in learning and memory [16, 17]. Early signs include difficulty recalling recent events, repeating questions within the same conversation, and relying on list-making or calendars [16, 18]. As the illness advances into major stages, patients experience severe word-finding deficits, language simplification, executive dysfunction, and loss of independence in instrumental activities of daily living such as managing finances, cooking, and handling medications [19-22]. Average lifespan following diagnosis ranges from **6 to 9 years** source 2. In contrast, **vascular neurocognitive disorder** often presents with a sudden or stepwise decline following cardiovascular events or small vessel ischemic disease, shortens lifespan by about **3 years**, and may initially spare memory [1, 2, 23, 24]. **Lewy body disease** presents with fluctuating cognition, early visual hallucinations, **REM sleep behavior disorder**, and spontaneous parkinsonism [25-28]. **Frontotemporal neurocognitive disorder** presents primarily with early behavioral disinhibition or prominent language impairment, often preserving spatial abilities and memory in early stages [1, 29]. Pathophysiology and Genetic Considerations. The biological hallmarks of **Alzheimer's disease** are neuritic **amyloid plaques** and neurofibrillary **tau tangles** source 3. **Vascular neurocognitive disorder** is caused by cortical and subcortical infarcts source 24. **Lewy body disease** is driven by alpha-synuclein inclusions within **Lewy bodies** source 24. Screening for the **ApoE e4 allele** is not recommended for routine clinical evaluation source 14. However, genetic testing is recommended when evaluating suspected early-onset cases occurring before **65 years of age**, which account for less than **5%** of all cases source 15. Routine laboratory evaluation for suspected major NCD includes a **CBC**, **TSH**, **B12** (with methylmalonic acid if B12 is low-normal), **folate**, **CMP**, **hepatic panel**, **syphilis VDRL**, **HIV**, and **urinalysis** to rule out reversible or contributing causes [30, 31]. Neuroimaging with a non-contrast **head CT** or **MRI** is indicated during the initial workup source 15. Pharmacotherapy and Safety Rules. **First-line** treatment for mild to moderate **Alzheimer's disease** utilizes **acetylcholinesterase inhibitors** (**donepezil**, **rivastigmine**, **galantamine**) [4, 5]. These agents increase synaptic acetylcholine levels, producing modest, time-limited cognitive improvements source 5. Common side effects are cholinergic, primarily **nausea**, **vomiting**, and **diarrhea** source 32. For moderate to severe stages, the **NMDA receptor antagonist** **memantine** (**Namenda**) is added to regulate pathologically elevated glutamate activity [4, 6]. Combination therapy with an **acetylcholinesterase inhibitor** and **memantine** is beneficial in earlier to moderate stages source 6. **Safety alert**: Avoid medications with strong anticholinergic properties, such as **tricyclic antidepressants** or first-generation antihistamines like **diphenhydramine**, because they worsen cognitive impairment, induce urinary retention, and precipitate acute delirium [33-36]. When treating co-occurring depression or anxiety, **SSRIs** like **sertraline** are preferred, but clinicians must monitor for **hyponatremia**, particularly when prescribed alongside thiazide diuretics or ACE inhibitors [12, 33, 37-39]. **Safety alert**: **Second-generation antipsychotics** carry a strict **boxed warning** when used in elderly patients with NCD-related psychosis or agitation due to a **1.6 to 1.7 times** increased risk of mortality, primarily from heart failure, sudden cardiac death, or pneumonia [7, 8, 40]. Antipsychotic prescribing must be restricted to severe agitation that compromises immediate safety [10, 41]. **Brexpiprazole** (**Rexulti**) holds a specific FDA indication for agitation in AD, but it retains the class **boxed warning** [7, 42]. In **Lewy body disease**, antipsychotics carry extreme neuroleptic sensitivity and can trigger severe extrapyramidal symptoms or neuroleptic malignant syndrome [4, 43, 44]. **Board trap**: Expecting psychotropic medications or **cholinesterase inhibitors** to return a patient to their pre-disease baseline source 9. These medications slow progression modestly but do not reverse underlying neuronal loss [9, 10]. Additionally, jumping to prescribe an antipsychotic for minor non-emergent behavioral outbursts or wandering is a major board trap [10, 32]. Non-pharmacologic strategies, including structured routines, reminiscence therapy, environmental simplification, door alarms, and caregiver support through adult day programs, are the required first step for non-emergent behaviors [32, 45-47]. Practice Questions for Board Mastery. Question 3. Mrs. Little is a 78-year-old woman with recently diagnosed **Alzheimer's disease** who presents for an office visit with her daughter. The daughter reports that Mrs. Little struggles with word finding, has difficulty following multi-step directions, appears apathetic at times, and recently had an angry verbal outburst triggered by a minor schedule change. Mrs. Little lives with her daughter's family, who wish to care for her at home as long as safely possible. When evaluating Mrs. Little's healthcare needs, which of the following are pertinent clinical options? Select all that apply: - A. A home safety evaluation should be conducted and appropriate modifications carried out. - B. Healthcare providers should be contacted promptly if Mrs. Little experiences a sudden change in mental status. - C. Behavioral difficulties frequently arise in individuals with **Alzheimer's disease** if their usual routine is disrupted. - D. Initiating a **cholinesterase inhibitor** will likely restore her mental status to a point nearly equivalent to her pre-disease baseline. - E. Mrs. Little should be evaluated for a concomitant mood disorder such as depression. - F. The most common adverse effects from **cholinesterase inhibitor** use include nausea and diarrhea. - G. A **second-generation antipsychotic** should be started immediately to prevent future angry outbursts. **Pause.** **Answer:** Options A, B, C, E, and F are correct [9, 32]. **Why It Is Correct:** Options A, B, C, E, and F represent evidence-based practice [9, 32]. Environmental safety and fall protection are essential for aging in place [48, 49]. Sudden mental status changes signal acute medical illness or delirium requiring urgent evaluation [49-51]. Routine disruptions trigger catastrophic reactions in AD source 52. Depressive symptoms affect up to **50%** of patients with major NCD and warrant screening and treatment [11, 32]. GI hypermotility causing nausea and diarrhea is the most common side effect of **acetylcholinesterase inhibitors** source 32. **Why the Other Choices Are Wrong:** - **Option D is incorrect** because **cholinesterase inhibitors** provide modest, temporary stabilization of cognitive decline but never restore patients to their pre-disease functional baseline [9, 10]. - **Option G is incorrect** because **second-generation antipsychotics** carry a **boxed warning** for increased mortality and should never be prescribed for non-emergent behavioral outbursts or emotional lability [10, 32, 40]. Question 4. Which of the following is the least likely characteristic of **Alzheimer's disease**? - A. Slowly developing impairment of cognitive function - B. Chronic condition without reversal - C. Perceptual disturbances including visual hallucinations early in the course - D. Progressive and irreversible course **Pause.** **Answer:** C source 53. **Why It Is Correct:** Early visual hallucinations and prominent perceptual disturbances are classic features of **Lewy body disease**, not **Alzheimer's disease** [26, 53]. In **Alzheimer's disease**, cognitive decline centers on memory impairment and executive dysfunction, while hallucinations typically appear only in advanced, severe stages [23, 53]. **Why the Other Choices Are Wrong:** - **A is incorrect** because a gradual, slowly progressive decline in cognitive function over months to years is a cardinal diagnostic requirement for AD [17, 53]. - **B is incorrect** because AD is a chronic, non-reversible neurodegenerative disorder [2, 53]. - **D is incorrect** because AD follows an inevitably progressive and irreversible trajectory, with an average survival of **6 to 9 years** post-diagnosis [2, 53]. Question 7. In what stage of **major neurocognitive disorder** do **acetylcholinesterase inhibitors** demonstrate the greatest clinical benefit? - A. Mild neurocognitive disorder - B. Early-onset non-Alzheimer's dementia - C. Mild to moderate **Alzheimer's disease** - D. Severe **Alzheimer's disease** **Pause.** **Answer:** C source 54. **Why It Is Correct:** **Acetylcholinesterase inhibitors** (**donepezil**, **rivastigmine**, **galantamine**) have FDA approval and demonstrated clinical efficacy specifically in mild to moderate **Alzheimer's disease** by enhancing central cholinergic transmission [4, 5, 54]. **Why the Other Choices Are Wrong:** - **A is incorrect** because **acetylcholinesterase inhibitors** are not routinely recommended or FDA-approved for **mild neurocognitive disorder** [12, 54]. - **B is incorrect** because cholinesterase inhibitors are specifically targeted to Alzheimer's pathology rather than non-specific early-onset dementias [4, 54]. - **D is incorrect** because while **donepezil** can be continued in severe stages, **memantine** or combination therapy is the primary indication for moderate to severe disease, whereas cholinesterase monotherapy demonstrates its greatest relative benefit in mild to moderate stages [4, 6, 54]. Next. Topic. Vascular Disease. Bottom Line Summary. * **Vascular neurocognitive disorder** is the second most common cause of major neurocognitive disorder, frequently co-occurring with **Alzheimer's disease** as a mixed neurocognitive disorder. * Shortens average lifespan by approximately 3 years following diagnosis, compared to a 6 to 9 year average survival in **Alzheimer's disease**. * Onset is characterized by a sudden or step-wise decline following cerebrovascular events, TIAs, or small vessel ischemic disease, rather than the smooth insidious onset seen in **Alzheimer's disease**. * Initial cognitive deficits disproportionately affect complex attention, processing speed, and executive function, while short-term memory may remain relatively preserved early on. * Pathophysiology stems from cortical and subcortical vascular infarcts, lacunar lesions, and small vessel ischemic brain injury. * **First-line** intervention centers on aggressive management of cardiovascular risk factors, including blood pressure control, diabetes management, lipid lowering, and antiplatelet therapy such as **aspirin**. * **Cholinesterase inhibitors** like **donepezil**, **rivastigmine**, and **galantamine** may provide modest symptomatic support for cognitive deficits, though they do not reverse vascular injury. Master Comparison Matrix: Vascular Disease Clinical Teaching. Core Features and Onset Pattern. **Vascular neurocognitive disorder** represents the second most frequent cause of major neurocognitive impairment in older adults source 1. Unlike the slow, insidious progression of **Alzheimer's disease**, vascular cognitive decline frequently manifests with a sudden onset or a distinct step-wise trajectory following discrete cardiovascular or cerebrovascular events source 2. Patients often experience sudden drops in functional capacity interspersed with periods of stability. **Board trap:** Exam items frequently attempt to mislead candidates by presenting a patient with cognitive decline and prompting for **Alzheimer's disease**. Pay close attention to the timeline. If the vignette describes a step-wise drop in executive function following a stroke, transient ischemic attack, or severe cardiovascular event, the correct diagnosis is **vascular neurocognitive disorder**. Pathophysiology and Vascular Risk Factors. The underlying biological mechanism involves cortical and subcortical ischemic infarcts, lacunar strokes, and chronic small vessel ischemic disease [3, 4]. Chronic hypoperfusion damages white matter tracts and subcortical structures responsible for rapid neural processing. **Safety alert:** Co-occurring **delirium** or post-stroke **major depressive disorder** occurs in a significant portion of vascular patients and can dramatically accelerate cognitive decline [5, 6]. Managing systemic vascular health is essential to prevent secondary ischemic events. Symptom Presentation and Cognitive Domains. While memory loss is the hallmark initial symptom of **Alzheimer's disease**, memory impairment in **vascular neurocognitive disorder** is variable and often absent during early stages source 2. Instead, early clinical impairment concentrates in executive function, complex attention, and processing speed [7, 8]. Patients struggle with multi-step planning, decision making, mental flexibility, and organizing daily tasks, whereas simple recall may remain intact initially [7, 9]. Diagnostic Differentiation. * **Alzheimer's disease:** Insidious onset, smooth progressive decline, early short-term memory deficits, neurofibrillary tangles and amyloid plaques, average survival 6 to 9 years post-diagnosis [1, 2, 10]. * **Vascular neurocognitive disorder:** Sudden or step-wise decline, focal neurological deficits, early executive function and attention impairment, subcortical/cortical infarcts, shortens lifespan by 3 years [1, 2, 10]. * **Lewy body disease:** Third most common subtype, early visual hallucinations, REM sleep behavior disorder, fluctuating cognition, severe parkinsonism, extreme neuroleptic sensitivity [3, 10-12]. * **Frontotemporal neurocognitive disorder:** Early behavioral disinhibition, apathy, loss of empathy, or primary progressive language breakdown with early relative preservation of memory [1, 13]. Pharmacologic and Non-Pharmacologic Management. **First-line:** Aggressive modification of cardiovascular risk factors is the primary clinical priority. This includes optimal control of hypertension, diabetes, and hyperlipidemia, alongside antiplatelet agents like **aspirin** and lifestyle interventions such as a Mediterranean heart-healthy diet and physical activity [14, 15]. For cognitive symptoms, **cholinesterase inhibitors** such as **donepezil**, **rivastigmine**, or **galantamine** may be utilized off-label or for co-occurring mixed vascular and Alzheimer's pathology to improve cholinergic neurotransmission [16, 17]. **SSRIs** are preferred for comorbid anxiety or post-stroke depression [18, 19]. Board Practice Questions. Question 1. Your patient with a major neurocognitive disorder develops severe bradycardia, gait disturbances, rigidity, and tremor after taking a low-dose second-generation antipsychotic for severe hallucinations. Which neurocognitive disorder subtype do you suspect? A. **Alzheimer's disease** B. **Vascular disease** C. **Frontotemporal disease** D. **Lewy body disease** Pause. Answer. **Keyed letter:** D **Why it is correct:** **Lewy body disease** features severe neuroleptic sensitivity [3, 16]. Administering even low-dose antipsychotics can trigger severe parkinsonism, marked rigidity, gait impairment, and autonomic instability [3, 17, 20]. **Why the other choices are wrong:** * A. **Alzheimer's disease** presents with progressive memory loss and does not exhibit extreme neuroleptic sensitivity [2, 3]. * B. **Vascular disease** presents with step-wise executive decline from ischemic infarcts without acute SGA-induced parkinsonism [2, 4]. * C. **Frontotemporal disease** presents primarily with early behavioral disinhibition or language breakdown rather than severe SGA sensitivity [1, 13]. **Test-taking pearl:** When a vignette describes severe parkinsonism or rigidity triggered by a low-dose antipsychotic, immediately select **Lewy body disease** [3, 20]. Question 2. Which of the following is the least likely characteristic of **Alzheimer's disease** when differentiating it from other neurocognitive disorder subtypes? A. A slowly developing impairment of cognitive function B. Chronic condition without reversal C. Perceptual disturbances including hallucinations D. Progressive and irreversible Pause. Answer. **Keyed letter:** C **Why it is correct:** Early visual hallucinations and perceptual disturbances are classic features of **Lewy body disease**, whereas they occur late or not at all in typical **Alzheimer's disease** [12, 21]. **Why the other choices are wrong:** * A. Slowly developing cognitive impairment is the hallmark presentation of **Alzheimer's disease** [2, 21]. * B. **Alzheimer's disease** is a chronic neurodegenerative disorder without reversal [10, 21]. * D. **Alzheimer's disease** follows a relentlessly progressive and irreversible trajectory [10, 21]. **Test-taking pearl:** Early visual hallucinations point directly to **Lewy body disease**, not **Alzheimer's disease** [12, 21]. Question 3. A 74-year-old male is evaluated for recent erratic behavior and fluctuating confusion lasting a few hours at a time up to three times per day over the past month. His caregiver reports he recently started a new medication. Which medication is least likely to cause these episodes? A. **Diphenhydramine** B. **Sertraline** C. **Haloperidol** D. **Diazepam** Pause. Answer. **Keyed letter:** B **Why it is correct:** **Sertraline** is an SSRI preferred in older adults and is least likely to precipitate acute delirium or fluctuating confusion [18, 22, 23]. **Why the other choices are wrong:** * A. **Diphenhydramine** has strong anticholinergic effects that frequently trigger delirium in elders [23, 24]. * C. **Haloperidol** can cause severe extrapyramidal signs, sedation, or paradoxical agitation in vulnerable older adults [23, 25]. * D. **Diazepam** is a long-acting benzodiazepine that causes sedation, ataxia, and cognitive impairment in older adults [23, 26]. **Test-taking pearl:** SSRIs like **sertraline** are preferred for mood in elders, whereas anticholinergics and long-acting sedatives frequently cause delirium [22-24]. Question 4. In what stage of major neurocognitive disorder do **cholinesterase inhibitors** demonstrate the most clinical benefit? A. **Mild neurocognitive disorder** B. Early **Alzheimer's disease** C. Mild to moderate **Alzheimer's disease** D. Severe **Alzheimer's disease** Pause. Answer. **Keyed letter:** C **Why it is correct:** **Cholinesterase inhibitors** such as **donepezil**, **rivastigmine**, and **galantamine** show their clearest clinical benefit in mild to moderate stages of dementia [16, 27, 28]. **Why the other choices are wrong:** * A. **Cholinesterase inhibitors** are not routinely recommended for **mild neurocognitive disorder** without major progression [18, 28]. * B. Early disease alone is incomplete, as clinical benefit extends through the moderate stage [16, 28]. * D. Severe stages typically require adding an NMDA antagonist like **memantine** [16, 29]. **Test-taking pearl:** Memorize that **cholinesterase inhibitors** are indicated for mild to moderate dementia, while **memantine** is added for moderate to severe stages [16, 28, 29]. Question 5. When conducting an initial diagnostic workup for an older adult presenting with acute, sudden-onset mental status changes, which test is least essential in the immediate initial delirium evaluation? A. Head CT scan B. Complete blood count C. Comprehensive metabolic panel D. Electrocardiogram Pause. Answer. **Keyed letter:** A **Why it is correct:** Laboratory studies (CBC, CMP) and an EKG are essential immediate initial tests to identify common metabolic, infectious, or cardiac causes of delirium before obtaining a head CT scan [30, 31]. **Why the other choices are wrong:** * B. A complete blood count is essential to rule out occult infection or anemia driving acute delirium [30, 31]. * C. A comprehensive metabolic panel is essential to assess electrolytes, renal function, hepatic function, and glucose [30, 31]. * D. An electrocardiogram is essential to rule out silent myocardial infarction or dysrhythmia causing acute cerebral hypoperfusion [30-32]. **Test-taking pearl:** Always rule out metabolic, infectious, and cardiac causes with basic labs and EKG before ordering neuroimaging for acute delirium [30, 31]. 🧠 Would you like to generate a practice quiz or flashcard set covering the remaining neurocognitive disorder subtypes like Frontotemporal or Lewy Body disease? Next. Topic. Lewy Body Disease (LBD). Lewy Body Disease (LBD). Bottom Line. - **Lewy body disease** is the third most common cause of major neurocognitive disorder, following **Alzheimer's disease** and vascular dementia. - Average age of diagnosis is **68 years old**, with death occurring around **75 years old**, progressing more rapidly than **Alzheimer's disease**. - Core diagnostic features include detailed spontaneous visual hallucinations, fluctuating cognition and alertness, **REM sleep behavior disorder**, and motor parkinsonism (**bradykinesia**, **rigidity**, postural instability). - Diagnostic timing rule: Motor parkinsonism presents within 1 year before or after the onset of cognitive decline. - **First-line**: Acetylcholinesterase inhibitors (**donepezil**, **rivastigmine**, **galantamine**) treat cognitive deficits and memory decline. - **Safety alert**: Extreme neuroleptic sensitivity exists. Traditional antipsychotics can precipitate severe extrapyramidal symptoms, rigidity, severe bradycardia, or fatal **neuroleptic malignant syndrome**. - **Board trap**: Assuming early short-term memory loss is required for diagnosis. Short-term memory loss is a late feature in **Lewy body disease**, whereas visual hallucinations and sleep disturbances appear early. - All antipsychotics carry an FDA **boxed warning** for increased mortality (1.6 to 1.7 times higher risk, primarily cardiovascular or pneumonia) in older adults with dementia-related psychosis. If severe agitation requires medication, low-dose **quetiapine** is best studied with the lowest motor risk. High-Yield Concept Map. Lewy Body Disease. - **What it is**: A progressive major neurocognitive disorder caused by abnormal intraneuronal alpha-synuclein protein deposits called **Lewy bodies** in cortical and subcortical brain regions. - **Why boards care**: It tests the ability to recognize non-memory early symptoms, differentiate diagnostic timelines, and avoid life-threatening psychotropic prescribing errors. - **Must know criteria / features**: Recurrent, detailed visual hallucinations presenting early; fluctuating attention and alertness; **REM sleep behavior disorder** featuring dream enactment; and parkinsonian motor signs (**bradykinesia**, **rigidity**, tremor, falls) developing within 1 year of cognitive decline. Mean age of diagnosis is **68 years old** and mean age of death is **75 years old**. - **Typical board clue**: An older adult presenting with vivid visual hallucinations, dream enactment during sleep, and new motor stiffness, or a patient who develops severe rigidity and bradycardia after receiving a low-dose antipsychotic. - **First-line approach**: Rule out medical causes of delirium. Initiate acetylcholinesterase inhibitors (**donepezil**, **rivastigmine**, **galantamine**) for cognitive support. - **When the answer changes**: If severe agitation or psychosis poses an immediate safety risk, consider low-dose **quetiapine** with extreme caution due to neuroleptic sensitivity. - **Safety alert**: Severe neuroleptic sensitivity can cause acute extrapyramidal collapse, catatonia, or **neuroleptic malignant syndrome**. All antipsychotics carry a **boxed warning** for increased mortality in dementia-related psychosis. Must Know for Boards. - Prevalence ranking: **Alzheimer's disease** is the most common major neurocognitive disorder, mixed/vascular dementia is second, and **Lewy body disease** is third. - Symptom sequence: **REM sleep behavior disorder** and visual hallucinations often precede major memory impairment. - Motor timeline rule: Parkinsonism occurring within 1 year of cognitive decline indicates **Lewy body disease**. Parkinsonism established for over 1 year before cognitive decline indicates Parkinson's disease dementia. - Pharmacologic sensitivity: D2 receptor blockade triggers severe parkinsonian reactions and autonomic instability. Compare and Distinguish. Lewy Body Disease vs. Alzheimer's Disease. - **Do not confuse**: Primary early symptoms and psychotropic tolerance differ significantly between these conditions. - **Think Lewy Body Disease when**: Patient presents with early visual hallucinations, **REM sleep behavior disorder**, fluctuating alertness, motor parkinsonism, and severe neuroleptic sensitivity. Short-term memory loss is late. - **Think Alzheimer's Disease when**: Patient presents with early short-term memory loss and insidious cognitive decline without early parkinsonism or early visual hallucinations. - **Priority difference**: Avoid traditional antipsychotics in **Lewy Body Disease** due to life-threatening sensitivity risks. - **What boards are really testing**: Ability to recognize non-memory early features and avoid unsafe antipsychotic prescribing. - **Classic distractor**: Ordering **haloperidol** or potent D2 blockers for hallucinations in an older adult with unrecognized **Lewy Body Disease**. Lewy Body Disease vs. Parkinson's Disease Dementia. - **Do not confuse**: The chronological relationship between motor and cognitive symptom onset determines the diagnosis. - **Think Lewy Body Disease when**: Cognitive decline occurs concurrently with parkinsonism or within 1 year of motor symptom onset. - **Think Parkinson's Disease Dementia when**: Well-established Parkinson's disease with motor symptoms exists for more than 1 year before cognitive decline develops. - **Priority difference**: Diagnostic classification rests strictly on the 1-year timeline threshold. - **What boards are really testing**: Precision with diagnostic timeframes in movement-related neurocognitive disorders. - **Classic distractor**: Diagnosing Parkinson's disease dementia when cognitive symptoms precede or occur simultaneously with motor signs. Common Board Traps. - **Trap**: Prescribing typical antipsychotics or potent D2 blockers for visual hallucinations in **Lewy body disease**. - **Why it looks right**: Hallucinations are distressing and traditionally managed with antipsychotics. - **Why it is wrong**: **Lewy body disease** involves extreme neuroleptic sensitivity, leading to severe rigidity, catatonia, or fatal **neuroleptic malignant syndrome**. - **Board rule to remember**: Avoid traditional antipsychotics in **Lewy body disease**; consider low-dose **quetiapine** only if severe safety risks exist. - **Trap**: Expecting short-term memory loss as the initial requirement to diagnose **Lewy body disease**. - **Why it looks right**: Short-term memory loss is the classic early finding in **Alzheimer's disease**. - **Why it is wrong**: **Lewy body disease** presents early with visual hallucinations, fluctuating attention, **REM sleep behavior disorder**, and executive dysfunction, while memory loss occurs later. - **Board rule to remember**: Absence of early short-term memory loss does not rule out **Lewy body disease**. Details. **Lewy body disease** stems from intraneuronal alpha-synuclein protein accumulations (**Lewy bodies**) distributed across subcortical and cortical structures, disrupting central cholinergic and dopaminergic pathways. Non-pharmacologic strategies focus on maintaining environmental structure, establishing fall prevention measures, supporting family caregivers to prevent burnout, and maintaining calm, non-confrontational daily routines. Standardized assessment tools such as the MoCA or SLUMS evaluate executive function, attention, and visual-spatial domains more effectively than memory-centric tools in patients with suspected **Lewy body disease**. Practice Questions. Question 1. Which of the following is the least likely characteristic of Alzheimer's disease? - A. Slowly developing impairment of cognitive function - B. Chronic condition without reversal - C. Perceptual disturbances including hallucinations - D. Progressive and irreversible Pause. Answer: C. Why it is correct: Perceptual disturbances such as visual hallucinations are characteristic early features of **Lewy body disease** rather than **Alzheimer's disease**. Why the other choices are wrong: - A. Slowly developing cognitive decline is a primary feature of **Alzheimer's disease**. - B. Chronic non-reversible decline is expected in **Alzheimer's disease**. - C. Correct answer because visual hallucinations are rare early in **Alzheimer's disease**. - D. Progressive and irreversible decline defines **Alzheimer's disease**. Test-taking pearl: Early visual hallucinations point toward **Lewy body disease** rather than **Alzheimer's disease**. Concept tested: Differential diagnosis of neurocognitive disorders. Question 2. Which of the following is least likely to be noted in the person with Lewy body disease? - A. Short-term memory loss - B. Bradykinesia and rigidity - C. Visual hallucinations - D. REM sleep behavior disorder Pause. Answer: A. Why it is correct: Prominent short-term memory loss is typical of early **Alzheimer's disease**, whereas motor parkinsonism, visual hallucinations, and **REM sleep behavior disorder** dominate early **Lewy body disease**. Why the other choices are wrong: - A. Correct answer because short-term memory loss is not an early hallmark of **Lewy body disease**. - B. **Bradykinesia** and **rigidity** are core motor features of **Lewy body disease**. - C. Spontaneous visual hallucinations are a cardinal diagnostic feature of **Lewy body disease**. - D. Dream enactment during sleep is a hallmark early feature of **Lewy body disease**. Test-taking pearl: Look for motor parkinsonism and **REM sleep behavior disorder** before memory loss when identifying **Lewy body disease**. Concept tested: Clinical presentation of **Lewy body disease**. Question 3. Your patient with major neurocognitive disorder develops severe bradycardia, gait disturbances, rigidity, and tremor after taking a low dose SGA for severe hallucinations. Which NCD type do you suspect? - A. Alzheimer's disease - B. Vascular disease - C. Frontotemporal disease - D. Lewy body disease Pause. Answer: D. Why it is correct: Patients with **Lewy body disease** display severe neuroleptic sensitivity, where low doses of antipsychotics trigger acute parkinsonism, severe **rigidity**, or **neuroleptic malignant syndrome**. Why the other choices are wrong: - A. **Alzheimer's disease** does not cause extreme neuroleptic sensitivity or acute severe parkinsonism. - B. Vascular disease causes step-wise cognitive decline from vascular events without severe neuroleptic sensitivity. - C. Frontotemporal disease presents with behavioral disinhibition or aphasia rather than neuroleptic sensitivity. - D. Correct answer due to severe sensitivity to neuroleptic medications. Test-taking pearl: Severe extrapyramidal symptoms or **rigidity** triggered by low-dose antipsychotics indicates **Lewy body disease**. Concept tested: Antipsychotic sensitivity in neurocognitive disorders. Active Recall Checkpoints. 1. What is the prevalence rank of **Lewy body disease** among major neurocognitive disorders? 2. What is the defining diagnostic timeline distinguishing **Lewy body disease** from Parkinson's disease dementia? 3. Which sleep disorder featuring dream enactment frequently precedes cognitive decline in **Lewy body disease**? 4. What dangerous adverse reaction can occur if a patient with **Lewy body disease** receives a traditional antipsychotic? 5. Which second-generation antipsychotic is best studied and preferred at low doses when severe agitation occurs in **Lewy body disease**? 6. What is the mean age of diagnosis and mean age of death for **Lewy body disease**? 7. Which medication class represents first-line pharmacotherapy for cognitive symptoms in **Lewy body disease**? Next Study Step. Study Fitzgerald Chapter 14: Delirium Assessment, Risk Factors, and the DELIRIUM Etiology Mnemonic. - **Why this is the best next step**: Completes the three Ds of geriatric psychiatry (depression, dementia, delirium) and reinforces differentiating acute fluctuating delirium from chronic fluctuating **Lewy body disease**. 💡 *Would you like to generate practice questions on differentiating delirium from dementia, or review the DELIRIUM etiology mnemonic next?* Next. Topic. Frontotemporal Disease (FTD/Pick’s). Bottom Line. * **Frontotemporal Disease (FTD / Pick's)** is a major neurocognitive disorder characterized by focal degeneration of the frontal and temporal lobes, presenting with prominent early behavioral, personality, or language changes while short-term memory is relatively preserved in early stages. * **Peak age of onset**: FTD typically presents at a younger age than **Alzheimer's disease**, with onset occurring between ages 40 and 65 (mean age in the 50s to 60s). * **First-line pharmacotherapy**: **Selective serotonin reuptake inhibitors (SSRIs)** like **sertraline** or **trazodone** are used to manage behavioral disinhibition, impulsivity, hyperorality, and compulsive symptoms. * **Safety alert**: **Cholinesterase inhibitors** (**donepezil**, **rivastigmine**, **galantamine**) and **memantine** are not indicated for FTD and can exacerbate agitation and behavioral dysregulation. * **Master matrix prevalence hierarchy**: **Alzheimer's disease** is the most common cause of major neurocognitive disorder (average post-diagnosis lifespan 6 to 9 years), followed by mixed AD and vascular disease, **Dementia with Lewy Bodies** (third most common, mean onset age 68, death at age 75), and **Vascular NCD** (shortens lifespan by 3 years). * **Severe neuroleptic sensitivity**: **Dementia with Lewy Bodies** carries extreme sensitivity to antipsychotics where low doses trigger severe parkinsonism, rigidity, or neuroleptic malignant syndrome; **quetiapine** is the preferred second-generation antipsychotic when treatment of severe agitation or hallucinations is required for safety. High-Yield Concept: Frontotemporal Disease (FTD / Pick's). - **What it is**: A major neurocognitive disorder caused by progressive focal atrophy of the frontal and temporal lobes, resulting in early social disinhibition, apathy, loss of empathy, hyperorality, compulsive behaviors, or primary progressive aphasia. - **Why boards care**: Exam questions evaluate your ability to distinguish FTD from **Alzheimer's disease** based on younger age of onset (40s to 60s) and early clinical domain impairment (behavior, personality, and executive function rather than short-term memory loss). - **Must-know features**: - Behavioral variant: marked loss of social decorum, apathy, loss of sympathy or empathy, hyperorality (dietary changes, compulsive eating), and repetitive, stereotypic behaviors. - Language variant: progressive difficulty with word finding, naming, speech fluency, or word comprehension. - Relative preservation of short-term memory and visuospatial orientation during early stages. - Pathophysiology: focal frontal and temporal cortical atrophy with Pick bodies (intraneuronal tau protein inclusions) or TDP-43 protein aggregates. - **First-line approach**: Non-pharmacological behavioral management, environment structuring, caregiver support, and **SSRIs** (**sertraline**, **citalopram**) or **trazodone** for behavioral control. - **Safety alert**: Avoid prescribing **cholinesterase inhibitors** or **memantine**, as they lack efficacy in FTD and frequently worsen neuropsychiatric symptoms and agitation. - **Board trap**: Misdiagnosing early FTD as late-onset mania, major depression, or a primary personality disorder due to dramatic behavioral disinhibition occurring without early memory impairment. Compare and Distinguish: MNCD Subtype Matrix. Frontotemporal Disease (FTD) vs. Alzheimer's Disease (AD). - **Think FTD when**: Patient presents at a younger age (40s to 60s) with early behavioral disinhibition, loss of empathy, apathy, or language difficulty while short-term memory remains intact early on. - **Think AD when**: Patient presents in older age with insidious, progressive short-term memory loss, learning deficits, and temporal/hippocampal atrophy. - **Treatment difference**: AD is managed with **cholinesterase inhibitors** (**donepezil**, **rivastigmine**, **galantamine**) for mild to moderate stages and **memantine** for moderate to severe stages; FTD avoids these agents and utilizes **SSRIs** for behavioral symptoms. Frontotemporal Disease (FTD) vs. Dementia with Lewy Bodies (DLB). - **Think FTD when**: Primary presentation centers on frontal social disinhibition, compulsive behaviors, or progressive aphasia without early motor parkinsonism or visual hallucinations. - **Think DLB when**: Patient presents with recurrent visual hallucinations, fluctuating alertness, REM sleep behavior disorder, and parkinsonian motor signs (rigidity, tremors, falls) occurring within 1 year of cognitive decline. - **Safety difference**: DLB carries extreme neuroleptic sensitivity where low-dose antipsychotics can trigger fatal rigidity or neuroleptic malignant syndrome; FTD avoids **cholinesterase inhibitors**. Frontotemporal Disease (FTD) vs. Vascular Neurocognitive Disorder. - **Think FTD when**: Gradual, progressive neurodegenerative frontal and temporal lobe atrophy leads to insidious social conduct or language breakdown. - **Think Vascular NCD when**: Cognitive decline occurs in a stepwise or abrupt pattern following cardiovascular events or strokes, accompanied by focal neurological deficits and cardiovascular risk factors. Board-Style Practice Questions. Question 1. Question: Which of the following is the least likely characteristic of Alzheimer's disease? - A. A slowly developing impairment of cognitive function - B. Chronic condition without reversal - C. Perceptual disturbances including hallucinations - D. Progressive and irreversible Pause. Best answer: C. Perceptual disturbances including hallucinations Why it is correct: Perceptual disturbances, specifically recurrent visual hallucinations, are classic early features of Dementia with Lewy Bodies rather than typical Alzheimer's disease. Alzheimer's disease typically presents with insidious short-term memory loss without early hallucinations. Why the other choices are wrong: - A. Slowly developing cognitive decline is a hallmark characteristic of Alzheimer's disease. - B. Alzheimer's disease is a chronic neurodegenerative condition without reversal. - D. Progressive and irreversible cognitive loss defines the typical course of Alzheimer's disease. Test-taking pearl: Visual hallucinations appearing early in cognitive decline should immediately point you toward Dementia with Lewy Bodies, not Alzheimer's disease. Concept tested: Neurocognitive disorder subtype differential diagnosis. Question 2. Question: Which of the following is least likely to be noted in a person with Lewy body disease? - A. Short-term memory loss - B. Bradykinesia and rigidity - C. Visual hallucinations - D. REM sleep behavior disorder Pause. Best answer: A. Short-term memory loss Why it is correct: Short-term memory loss is typically preserved during the early stages of Lewy body disease compared to Alzheimer's disease. Lewy body disease characteristically presents early with parkinsonian motor signs, visual hallucinations, fluctuating cognition, and REM sleep behavior disorder. Why the other choices are wrong: - B. Bradykinesia and rigidity are core parkinsonian motor features of Lewy body disease. - C. Recurrent, detailed visual hallucinations are a core diagnostic feature of Lewy body disease. - D. REM sleep behavior disorder where patients physically act out dreams is a prominent early feature of Lewy body disease. Test-taking pearl: When short-term memory is relatively preserved but motor parkinsonism, fluctuating attention, and dream enactment appear, select Lewy body disease over Alzheimer's disease. Concept tested: Clinical presentation of Dementia with Lewy Bodies. Question 3. Question: In what stage of major neurocognitive disorder do cholinesterase inhibitors demonstrate the most benefit? - A. Mild neurocognitive disorder - B. Early Alzheimer's disease - C. Mild to moderate Alzheimer's disease - D. Severe Alzheimer's disease Pause. Best answer: C. Mild to moderate Alzheimer's disease Why it is correct: Cholinesterase inhibitors (**donepezil**, **rivastigmine**, **galantamine**) demonstrate their clearest evidence-based benefit during the mild to moderate stages of Alzheimer's disease. Why the other choices are wrong: - A. Cholinesterase inhibitors are not routinely recommended for mild neurocognitive disorder. - B. Early Alzheimer's disease is less precise than the established clinical standard indication of mild to moderate Alzheimer's disease. - D. In severe Alzheimer's disease, the NMDA receptor antagonist **memantine** is added, as cholinesterase inhibitor monotherapy provides limited benefit. Test-taking pearl: Reserve cholinesterase inhibitors for established mild to moderate Alzheimer's disease; do not initiate them for mild neurocognitive disorder or Frontotemporal Disease. Concept tested: Pharmacotherapy staging in neurocognitive disorders. Question 4. Question: Your patient with major neurocognitive disorder develops severe bradycardia, gait disturbances, rigidity, and tremor after taking a low-dose second-generation antipsychotic for severe hallucinations. Which neurocognitive disorder subtype do you suspect? - A. Alzheimer's disease - B. Vascular disease - C. Frontotemporal disease - D. Lewy body disease Pause. Best answer: D. Lewy body disease Why it is correct: Patients with Lewy body disease exhibit severe neuroleptic sensitivity. Administering even low-dose second-generation antipsychotics can precipitate dramatic extrapyramidal side effects, severe rigidity, parkinsonism, or neuroleptic malignant syndrome. Why the other choices are wrong: - A. Alzheimer's disease does not exhibit the profound neuroleptic sensitivity seen in Lewy body disease. - B. Vascular disease presents with stepwise vascular decline without acute neuroleptic-induced parkinsonism. - C. Frontotemporal disease presents with early behavioral or language changes and does not carry the classic neuroleptic sensitivity of Lewy body disease. Test-taking pearl: Severe EPS or parkinsonism after a single low dose of an antipsychotic in a patient with cognitive decline is a classic board clue for Dementia with Lewy Bodies. Concept tested: Pharmacological sensitivity in neurocognitive disorder subtypes. 🧠 Want to review another neurocognitive subtype like Vascular NCD or delve into the Delirium etiology mnemonic next? Next. End of this drive.